Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

NCT02794571 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

518

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Tumors

Interventions

DRUG: Atezolizumab
DRUG: Tiragolumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Etoposide
DRUG: Capecitabine
DRUG: Bevacizumab
DRUG: Pembrolizumab

Sponsor

Genentech, Inc.